JP2022512544A5 - - Google Patents
Info
- Publication number
- JP2022512544A5 JP2022512544A5 JP2021512914A JP2021512914A JP2022512544A5 JP 2022512544 A5 JP2022512544 A5 JP 2022512544A5 JP 2021512914 A JP2021512914 A JP 2021512914A JP 2021512914 A JP2021512914 A JP 2021512914A JP 2022512544 A5 JP2022512544 A5 JP 2022512544A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody molecule
- virus
- seq
- antibody
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024059450A JP7681151B2 (ja) | 2018-09-03 | 2024-04-02 | 新規抗体およびヌクレオチド配列、ならびにそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18192311.1A EP3617230A1 (en) | 2018-09-03 | 2018-09-03 | Novel antibodies and nucleotide sequences, and uses thereof |
| EP18192311.1 | 2018-09-03 | ||
| PCT/EP2019/073488 WO2020049001A1 (en) | 2018-09-03 | 2019-09-03 | Novel antibodies and nucleotide sequences, and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059450A Division JP7681151B2 (ja) | 2018-09-03 | 2024-04-02 | 新規抗体およびヌクレオチド配列、ならびにそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512544A JP2022512544A (ja) | 2022-02-07 |
| JP2022512544A5 true JP2022512544A5 (enExample) | 2022-06-15 |
| JP7515461B2 JP7515461B2 (ja) | 2024-07-12 |
Family
ID=63490358
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512914A Active JP7515461B2 (ja) | 2018-09-03 | 2019-09-03 | 新規抗体およびヌクレオチド配列、ならびにそれらの使用 |
| JP2024059450A Active JP7681151B2 (ja) | 2018-09-03 | 2024-04-02 | 新規抗体およびヌクレオチド配列、ならびにそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024059450A Active JP7681151B2 (ja) | 2018-09-03 | 2024-04-02 | 新規抗体およびヌクレオチド配列、ならびにそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12291569B2 (enExample) |
| EP (2) | EP3617230A1 (enExample) |
| JP (2) | JP7515461B2 (enExample) |
| KR (1) | KR102866553B1 (enExample) |
| CN (2) | CN112912398B (enExample) |
| AU (1) | AU2019333862B2 (enExample) |
| BR (1) | BR112021003916A2 (enExample) |
| CA (1) | CA3111153A1 (enExample) |
| IL (1) | IL281198A (enExample) |
| MX (1) | MX2021002500A (enExample) |
| WO (1) | WO2020049001A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3552615B8 (en) | 2014-07-16 | 2022-03-02 | Transgene | Oncolytic virus for expression of immune checkpoint modulators |
| TW202321458A (zh) * | 2021-09-22 | 2023-06-01 | 瑞典商生物創新國際公司 | 新穎抗體組合及其用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0606217B2 (en) | 1991-06-27 | 2008-12-03 | Bristol-Myers Squibb Company | Ctl4a receptor, fusion proteins containing it and uses thereof |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| HRP20130077A2 (hr) | 1998-12-23 | 2013-07-31 | Pfizer Inc. | Humana monoklonalna protutjela za ctla-4 |
| CN102766210B (zh) | 1999-08-24 | 2015-07-08 | E.R.施贵宝&圣斯有限责任公司 | 人ctla-4抗体及其应用 |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
| ES2611975T3 (es) | 2006-06-20 | 2017-05-11 | Transgene S.A. | Procedimiento para producir poxvirus y composiciones de poxvirus |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| US8012738B2 (en) | 2007-05-14 | 2011-09-06 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
| US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
| BRPI0820576B1 (pt) | 2007-11-19 | 2021-10-19 | Transgène S.A. | Uso de um poxvírus oncolítico compreendendo um gene i4l e/ou f4l defectivo ou uma composição compreendendo o mesmo |
| EP2240573A4 (en) | 2008-02-12 | 2011-08-31 | Sanofi Pasteur Ltd | METHODS OF USING ION EXCHANGE CHROMATOGRAPHY AND DIFFUSION EXCLUSION CHROMATOGRAPHY FOR PURIFYING POXVIRUS |
| NZ596595A (en) | 2009-05-12 | 2013-05-31 | Transgene Sa | Method for orthopoxvirus production and purification |
| GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| ES2813413T3 (es) | 2011-08-05 | 2021-03-23 | Sillajen Biotherapeutics Inc | Métodos y composiciones para la producción de virus vaccina |
| US9789182B2 (en) | 2012-10-23 | 2017-10-17 | Bristol-Myers Squibb Company | Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer |
| EP3552615B8 (en) * | 2014-07-16 | 2022-03-02 | Transgene | Oncolytic virus for expression of immune checkpoint modulators |
| US10196445B1 (en) * | 2015-03-17 | 2019-02-05 | Bristol-Myers Squibb Company | Ipilimumab variant with enhanced ADCC |
| SI3389699T1 (sl) * | 2015-12-15 | 2024-07-31 | OncoC4, Inc. | Himerna in humanizirana monoklonska protitelesa proti humanemu ctla4 in uporabe le - teh |
| WO2017120612A1 (en) * | 2016-01-10 | 2017-07-13 | Modernatx, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
| NL2017270B1 (en) * | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
| FI3551660T3 (fi) | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä |
| AU2017414149B2 (en) * | 2017-05-19 | 2025-05-15 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) |
-
2018
- 2018-09-03 EP EP18192311.1A patent/EP3617230A1/en not_active Withdrawn
-
2019
- 2019-09-03 US US17/272,740 patent/US12291569B2/en active Active
- 2019-09-03 JP JP2021512914A patent/JP7515461B2/ja active Active
- 2019-09-03 CA CA3111153A patent/CA3111153A1/en active Pending
- 2019-09-03 EP EP19761869.7A patent/EP3847193A1/en active Pending
- 2019-09-03 CN CN201980055914.9A patent/CN112912398B/zh active Active
- 2019-09-03 AU AU2019333862A patent/AU2019333862B2/en active Active
- 2019-09-03 BR BR112021003916-3A patent/BR112021003916A2/pt unknown
- 2019-09-03 CN CN202411416221.7A patent/CN119161482A/zh active Pending
- 2019-09-03 WO PCT/EP2019/073488 patent/WO2020049001A1/en not_active Ceased
- 2019-09-03 MX MX2021002500A patent/MX2021002500A/es unknown
- 2019-09-03 KR KR1020217009505A patent/KR102866553B1/ko active Active
-
2021
- 2021-03-02 IL IL281198A patent/IL281198A/en unknown
-
2024
- 2024-04-02 JP JP2024059450A patent/JP7681151B2/ja active Active
-
2025
- 2025-04-02 US US19/098,185 patent/US20250257135A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20260059676A (ko) | 항-tigit 항체, 항-pvrig 항체 및 이들의 조합 | |
| EA034921B1 (ru) | Модуляция стимулирующих и нестимулирующих миелоидных клеток | |
| CN112703012A (zh) | 治疗癌症的方法 | |
| KR20180012864A (ko) | Cd38과 특이적으로 결합하는 항체에 의한 고형 종양의 면역 조절 및 치료 | |
| JP2024091656A5 (enExample) | ||
| CN114630838A (zh) | 新的抗cd25抗体 | |
| JP7593646B2 (ja) | Ｂａｆｆ－ｒ／ｃｄ１９を標的としたキメラ抗原受容体修飾ｔ細胞とその使用 | |
| US20230002504A1 (en) | Receptors providing targeted costimulation for adoptive cell therapy | |
| JP2020512983A (ja) | 最適化された多機能性ｔ細胞を含むキメラ受容体ｔ細胞を使用する治療 | |
| KR102950505B1 (ko) | M2 결함성 폭스바이러스 | |
| CN114258401B (zh) | 对cd38具有特异性的抗体及其用途 | |
| US20250257135A1 (en) | Novel antibodies and nucleotide sequences, and uses thereof | |
| TW202515608A (zh) | Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途 | |
| JP2024534550A5 (enExample) | ||
| WO2023046777A1 (en) | Novel combinations of antibodies and uses thereof | |
| WO2022035793A1 (en) | Antibodies and fragments specific for b-cell maturation antigen and uses thereof | |
| WO2024102704A2 (en) | Ipsc-derived nk cell targeting mica/b for solid tumor treatment | |
| EP4642806A2 (en) | Tcr-vbeta specific therapeutic molecules and uses thereof | |
| RU2021108970A (ru) | Новые антитела и нуклеотидные последовательности и их применение | |
| CN114616245B (zh) | 一种抗cd38的抗体及其用途 | |
| WO2022147481A1 (en) | Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen | |
| CN116917318A (zh) | 抗cd25抗体 | |
| TWI920354B (zh) | 抗ｃｃｒ８抗體 | |
| US20250249278A1 (en) | Methods for controlling the tumor cell killing by light | |
| Gokcen | Development of an MSC-based immune checkpoint inhibiting cell therapy |